Patients with NSCLC and Brain Metastases at Baseline Derive Limited Benefit from Mobocertinib

Article

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

The use of mobocertinib (Exkivity) demonstrated limited intercranial activity in patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer (NSCLC) with brain metastasis at presentation, according to study findings presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

The data, however, indicated that patients who did not have brain metastases at enrollment onto the trial, but their disease progressed to the brain after initial mobocertinib treatment derived a benefit from remaining on study therapy.

“Patients with disease progression in the brain may derive overall benefit from ongoing mobocertinib treatment with combination [radiotherapy] to treat the brain lesions,” the authors wrote in their presentation.

This 3-part, open label, multicenter study (NCT02716116) comprised 114 patients [median age, 60 years; 66% female; 60% Asian) with an ECOG status 0 to 1 who had at least 1 or more prior lines of therapy for locally advanced/metastatic EGFR exon 20 insertion-positive NSCLC. At baseline, 35% of patients had brain metastases.

Patients received mobocertinib at 160 mg once daily and were allowed to continue treatment beyond progressive disease at the discretion of the investigator if there was determined to be a clinical benefit. Additionally, patients with brain metastases were required to have the brain lesions treated and no symptoms of such prior to enrollment.

Confirmed objective response rate (cORR) was 28% (n = 32;) and median duration of response (DOR) was 17.5 months in the overall platinum-pretreated cohort (n = 64). Additionally, cORR was 34% (n = 25) among previously treated patients with no baseline brain metastases, compared with 18% (n = 7) among those with baseline metastases; and progression free survival was 9.2 and 3.7 months, respectively.

Among patients in the platinum-pretreated cohort, 21 (33%) had a first site of the disease involving the brain and 11 (17%) had first site of disease progression in the brain only. Of those 21 patients, 81% remained on mobocertinib beyond disease progression and 19% continued treatment for at least 6 months. And out of 43 patients who had first site of disease progression that did not involve the brain, 65% continued treatment with mobocertinib — 9% for at least 6 months.

“These results suggest that mobocertinib may have limited intercranial activity given the high frequency of first PD in brain (25%) and numerically IRC-assessed cORR in patients with baseline brain metastases,” the authors wrote in the abstract.

Of the 21 patients with first site of disease progression in the brain, 7 received brain radiotherapy and remained on mobocertinib (3 patients for 6 months or more and 1 patient for 12 months or more). Additionally, 12 patients remained on this treatment but did not receive radiotherapy.

“Optimal strategies for treating advanced EGFR exon-driven NSCLC with brain metastasis warrant continued investigation,” the authors concluded in their abstract.

Reference

Jaane P, Ramalingam S, Yang J, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD. J Clin Oncol. 2022; 40 (suppl_16):9099. doi: 10.1200/JCO.2022.40.16_suppl.9099

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content